Two-Drug combo aims to keep blood cancer at bay
NCT ID NCT04062266
Summary
This study is testing whether a two-drug combination can help keep acute myeloid leukemia (AML) from returning in patients who have achieved remission. The trial involves 50 adults with AML who have responded to initial treatment but are not candidates for stem cell transplant. Participants receive the drugs azacitidine and venetoclax for up to two years to see if this maintenance therapy can extend their time in remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.